Cormorant Asset Management, LP Omeros Corp Transaction History

Cormorant Asset Management, LP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.67 - $8.54 $5.39 Million - $8.11 Million	-950,000 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$13.4 - $16.3 $3.35 Million - $4.08 Million	-250,000 Reduced 20.83%	950,000 $13.1 Million
Q2 2021 Aug 16, 2021	SELL	$14.81 - $19.13 $31.1 Million - $40.2 Million	-2,100,030 Reduced 63.64%	1,200,000 $17.8 Million
Q1 2021 May 17, 2021	SELL	$14.52 - $23.53 $10.2 Million - $16.5 Million	-699,970 Reduced 17.5%	3,300,030 $58.7 Million
Q4 2020 Feb 16, 2021	SELL	$10.14 - $15.19 $10.1 Million - $15.2 Million	-1,000,000 Reduced 20.0%	4,000,000 $57.1 Million
Q3 2020 Nov 16, 2020	BUY	$9.57 - $21.32 $21.3 Million - $47.4 Million	2,225,000 Added 80.18%	5,000,000 $50.5 Million
Q2 2020 Aug 14, 2020	BUY	$12.21 - $16.99 $3.07 Million - $4.27 Million	251,300 Added 9.96%	2,775,000 $40.8 Million
Q1 2020 May 15, 2020	BUY	$9.03 - $19.72 $9.02 Million - $19.7 Million	998,700 Added 65.49%	2,523,700 $33.7 Million
Q4 2019 Feb 14, 2020	BUY	$13.01 - $17.15 $6.83 Million - $9 Million	525,000 Added 52.5%	1,525,000 $21.5 Million
Q3 2018 Nov 14, 2018	SELL	$17.73 - $26.69 $5.57 Million - $8.38 Million	-314,118 Reduced 23.9%	1,000,000 $24.4 Million
Q1 2018 May 15, 2018	BUY	$9.0 - $20.16 $3.95 Million - $8.85 Million	439,118 Added 50.18%	1,314,118 $14.7 Million
Q4 2017 Feb 14, 2018	SELL	$13.26 - $22.86 $10.9 Million - $18.9 Million	-825,000 Reduced 48.53%	875,000 $17 Million
Q3 2017 Nov 14, 2017	BUY	$19.76 - $24.9 $33.6 Million - $42.3 Million	1,700,000	1,700,000 $36.8 Million

120

25.6M

228K

630K

Ticker OMER
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,730,000
Market Cap $423M
Description
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.